Immunoassays Service

Immunoassays are fundamental analytical tools in preclinical and clinical drug development, enabling the high-sensitivity and high-specificity detection, quantification, and characterization of proteins and biomolecules based on the principle of antigen-antibody specific recognition. Alfa Cytology provides comprehensive immunoassay services to support target validation, pharmacodynamic assessment, immunogenicity evaluation, and biomarker discovery across your oncology drug development programs.

Introduction to Immunoassays

Immunoassays serve as a critical analytical bridge connecting molecular-level protein information with functional biological outcomes, delivering qualitative, semi-quantitative, and quantitative data that are essential for understanding drug efficacy, safety, and mechanism of action. Through diverse and well-validated immunoassay platforms, researchers can precisely measure drug concentrations in biological matrices for pharmacokinetic profiling, monitor anti-drug antibody (ADA) and neutralizing antibody (Nab) responses for immunogenicity risk assessment, track disease-relevant or pharmacodynamic biomarkers to support patient stratification, and visualize target protein expression levels, post-translational modifications, as well as protein-protein interactions to elucidate mechanisms of action. These data directly support lead compound screening, dose-escalation decisions, toxicity mitigation strategies, and clinical trial design, providing indispensable analytical evidence that ultimately accelerates the translational path from drug discovery to clinical application.

Fig. 1 Profiling protein expression using microfluidic western blotting in circulating tumour cells. (Budhbaware T, et al.; 2024)

Our Services

Leveraging the technology platforms of its Tumor Microenvironment Research Center, Alfa Cytology provides comprehensive immunoassay services designed to precisely profile, quantify, and track immunological events throughout the course of cancer therapy. Whether your drug candidates are small-molecule targeted modulators or large-molecule biologics, our immunoassay platforms deliver accurate data on target binding, functional activity, and microenvironmental immune responses, enabling comprehensive evaluation of the biological effects of your therapeutics in vivo.

Our immunology platform utilizes ELISA as the core quantitative tool, Western Blot as the fundamental validation method, IP/Co-IP for dissecting protein interaction networks, EMSA and ChIP for in-depth investigation of transcriptional regulatory mechanisms, and monoclonal antibody production to ensure the supply of critical reagents—forming a complete technological closed loop from tool development to mechanistic validation.

Test Types

Supported Therapeutic Modalities

Our immunoassay services broadly support diverse cancer therapy R&D, delivering precise quantitative and qualitative immunological data for target engagement validation, immunogenicity risk assessment, pharmacodynamic monitoring, and mechanistic elucidation to inform your critical R&D decisions.

Small Molecule	Therapeutic Antibody	Cell Therapy	Gene Therapy
Cancer Vaccine	Peptide Therapy	Nucleic Acid Therapeutics	Oncolytic Viral Therapy

Available Model Systems and Biological Matrices

Our immunoassay services are applicable to a wide range of cancer research models, providing reliable immunological data support for target validation, pharmacodynamic evaluation, and immunogenicity assessment across different stages of drug development.

• In Vitro Cell Models: Tumor cell lines, primary tumor cells, gene-edited cell lines, immune cell co-culture systems.
• 3D Models: Patient-derived organoids (PDO), 3D culture models.
• In Vivo Animal Models: Cell-derived xenograft (CDX) mouse models, patient-derived xenograft (PDX) models, genetically engineered mouse models (GEMM), humanized immune system mouse models.
• Ex Vivo Biological Matrices: Serum, plasma, cerebrospinal fluid, tissue homogenates, and cell culture supernatants.